Prelude Therapeutics annual revenue
2022
2023
2024
2025
Prelude Therapeutics Revenue Growth & History (PRLD)
Prelude Therapeutics reported $12.1M in revenue for fiscal 2025, an increase of 73.43% from the previous fiscal year.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.1M | $5.1M | +73.43% |
| 2024 | 2024-12-31 | $7.0M | $7.0M | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | — | — |
Prelude Therapeutics quarterly revenue
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.7M | $5.7M | — |
| Q1 2026 | 2026-03-31 | $4.6M | $4.6M | — |
| Q4 2025 | 2025-12-31 | $5.6M | — | — |
| Q3 2025 | 2025-09-30 | $6.5M | $3.5M | +116.67% |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $3.0M | — | — |
Prelude Therapeutics revenue growth trends
Prelude Therapeutics's latest reported quarter, Q2 2026, generated $5.7M in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...
